Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | TNG348 |
| Synonyms | |
| Therapy Description |
TNG348 selectively inhibits USP1, potentially resulting in decreased tumor cell viability and inhibition of tumor growth (PMID: 39886906). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| TNG348 | TNG 348|TNG-348 | USP1 inhibitor 7 | TNG348 selectively inhibits USP1, potentially resulting in decreased tumor cell viability and inhibition of tumor growth (PMID: 39886906). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06065059 | Phase Ib/II | TNG348 Olaparib + TNG348 | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors | Terminated | USA | 0 |